Published on: March 14, 2015
by Jessica Berman for Voice of America:
Alzheimer’s disease begins with mild memory impairment. There are currently no effective treatments for the neurodegenerative disease, which causes severe dementia. But researchers at Johns Hopkins University in the U.S. state of Maryland are hopeful that a generic drug now used to treat seizures can improve memory in the early stages of Alzheimer’s, even reversing the condition.
Levetiracetam, which goes by the brand name Keppra, is part of the drug arsenal used to treat epilepsy. The anti-seizure medicine seems to quiet the part of the brain called the hippocampus, that is over-activated in those with Alzheimer’s. The hippocampus is involved in memory.
Arnold Bakker, a professor of psychiatry at Johns Hopkins, says a recent study has helped doscover the drug’s newfound benefits.
“And what the medication does is it normalizes this increased activation, this dysfunctional activation,” he said. “And when you do that, it turns out that you improve their memory function. People who take the medication, [their] memory improved compared to when they are not on the medication.”
The study, which Bakker conducted with colleagues, involved 84 participants, 17 of whom were normal, healthy older adults. The others had symptoms of pre-dementia. The average age of the subjects was 70.
Researchers found there was a significant improvement on memory tests in those given a very low dose of the drug – between 1/10th and 1/15th of the dose used to treat epilepsy – compared to participants who got placebo.
Bakker hopes that levetiracetam might be able to stop the mental decline seen in patients suspected of having Alzheimer’s.
“The idea is to treat [Alzheimer’s] as early as possible, to prevent the onset of brain damage that results from the disease process,” he said.
Bakker says the long-term benefit of the drug still needs to be established, but he is excited that a treatment for Alzheimer’s may have been found.
“You know, I am a research scientist so I am always very careful,” he said. “We need to do some more studies but so far, this is extremely promising as far as I am concerned and we are very excited about it.”
The medication dose needed to treat Alzheimer’s is very small, but Bakker says it is currently only available in the higher dose used for epilepsy treatment.
A study of the drug was published in the journal NeuroImage: Clinical.
Older people who report greater levels of social engagement have more robust gray matter in regions of the brain relevant in dementia, according to new research led by scientists at the University of Pittsburgh Graduate School of...
In a new study, University of Nebraska–Lincoln sociologist Marc A. Garcia explored how educational attainment can benefit cognitive health in later life, and whether there are differences in its benefits among minorities. Garcia and his co-authors...
A genetic variation in some people may be associated with cognitive decline that can’t be explained by deposits of two key proteins associated with Alzheimer’s disease, amyloid β and tau, according to a study...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.